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Abstract
Background: Despite access to various pharmacotherapies and counseling support to aid cessation, smokers
typically demonstrate quit rates below 50%. This report describes the results of a Phase 2a study exploring the
efficacy of a liquid nicotine delivery system as an aid to smoking cessation assessed after 12 weeks of therapy.
Methods: A single-arm Phase 2a study was conducted. Community-based smokers (ages 18+ years, smoking at
least 10 cigarettes daily for the past year and interested in making a quit attempt) were recruited and completed
clinic visits at 2 week intervals over the 12 week study period where carbon monoxide levels were assessed and
the Smoke-Break product was rated on taste and overall satisfaction. Participants were provided with a supply of
liquid nicotine cigarettes (e.g., Smoke-Break) at each clinic visit. A total of 69 smokers were enrolled and received
the intervention product (intention to treat group, ITT) and 52 smokers verified participation (according to protocol
group, ATP).
Results: The cessation rate at 12 weeks after the baseline visit, assessed as the bioverified point prevalence of
abstinence, was 71.1% (95% confidence interval [CI] 58.8%-83.5%) in the ATP group and 53.6% (41.8%-65.4%) in the
ITT group. Participants rated the liquid nicotine delivery system highly and also expressed general satisfaction. Few
adverse events were identified with no serious adverse events.
Conclusions: These results support the efficacy of the liquid nicotine delivery system in smoking cessation. If this
nicotine delivery product proves to be effective in larger trials, it could represent an inexpensive, readily accessible
and well-tolerated agent to promote smoking cessation.
Trial Registration: This trial is registered at clinicaltrials.gov as study NCT00715871.
Background
Cigarette smoking represents the single most avoidable
cause of premature death in the United States (US) and
is responsible for at least 443,000 deaths annually[1].
While the prevalence of smoking in the US has declined
over the past half century, the current smoking rate is
about 20%, and with about 40 million adult smokers,
this behavior will continue to influence rates of prema-
ture morbidity and mortality for years to come[2]. Most
smokers report that they want to quit and approxi-
mately 40% attempt to stop smoking annually. Unfortu-
nately, most quit attempts are unplanned and usually
only last a few days or weeks and are unsupported by
the provision of pharmacotherapy and counseling
support. Difficulty quitting is best predicted by how
much one smokes on a daily basis and smoking within
30 minutes of waking up each day, both of which are
measures of nicotine dependence [3,4].
The Public Health Service guidelines for treating
tobacco use and dependence, last updated in 2008,
endorse the use of several proven pharmacotherapies for
cessation including nicotine replacement (e.g., patch,
lozenge, gum/resin, inhaler, and nasal spray), bupropion
(Wellbutrin®/Zyban®) and varenicline (Chantix®), as well
as the combination of counseling support and pharma-
cotherapy [5,6]. Quit rates for nicotine replacement
therapy (NRT) range between 20-24%,[7] compared to
30% for bupropion [8] and 44% for varenicline [9,10].
While somewhat different definitions for cessation, and
variable time intervals were used across these studies,
complicating direct comparisons, bupropion and vareni-
cline have greater efficacy, but require an office visit to
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pared to several formulations of NRT available over the
counter. As a result, population efficacy for a smoking
cessation product reflects the combination of product
effectiveness and population reach.
This report describes the results of a Phase 2a study
exploring the efficacy of a liquid nicotine delivery sys-
tem as an aid to smoking cessation assessed after 12
weeks of therapy.
Methods
Objective
To explore the efficacy of the liquid nicotine delivery
product as an aid to smoking cessation as assessed after
12 weeks of therapy. Secondary objectives included an
assessment of product taste, overall satisfaction, and
monitoring of adverse events.
Design
A single arm Phase 2a study examining the efficacy of a
liquid nicotine cigarette as an aid to smoking cessation.
Participants
Eligibility criteria included smokers ages > = 18 years,
10+ cigarettes daily, smoking for at least the past year,
interest in making a quit attempt, not using any other
form of nicotine replacement therapy, and no known
allergy to any components of the liquid nicotine cigar-
ette (Smoke-Break). Pregnant or nursing females, per-
sons reporting a history of heart disease or diabetes,
and/or use of a prescription medication for depression
or asthma were ineligible to participate. Women with
child bearing potential were advised to use appropriate
birth control methods during their course of treatment.
Smokers were recruited from the community via tele-
vision news stories, flyers and word of mouth which
generated calls from about 175 individuals. As shown in
Figure 1, 75 smokers who appeared to be eligible were
invited to a baseline visit.
During the baseline visit, eligibility was confirmed,
study procedures were reviewed, informed consent was
completed, and an initial 2 week supply of the Smoke-
Break product was distributed. All participants were
instructed to stop smoking by their follow-up appoint-
ment in 2 weeks. General materials on quitting smoking
were available at the baseline visits. Participants were
also asked to confirm their participation and their quit
date by leaving a phone message within 72 hours of
their baseline visit. The intention to treat (ITT) group
included all participants who completed informed con-
sent at the baseline visit and received an initial supply
of Smoke-Break product (n = 69) while the according to
protocol (ATP) group included all participants who con-
firmed participation (n = 52). This research study was
reviewed and approved by the New England Institu-
tional Review Board (#07-211).
Intervention
Participants were provided with liquid nicotine cigar-
ettes (e.g., Smoke-Break product) which are plastic tubes
containing a 1.5 milligram (mg) dose of nicotine in a
naturally flavored, artificially sweetened gel. All compo-
nents are FDA-approved for use in food and pharma-
ceutical products.
Subjects were advised on use of Smoke-Break liquid
cigarette tubes based on their daily nicotine intake esti-
mated using the published nicotine content (in milli-
grams, mg) of their usual cigarette brand multiplied by
the number of cigarettes smoked per day. This estimate
of total daily nicotine intake was divided by 1.5 (the
amount of nicotine (in mg) in each liquid cigarette tube
to yield the total tubes of product to be used each day.
Participants were advised not to exceed 4 tubes within a
one hour period or 40 liquid cigarette tubes in a day.
Subjects were provided a sufficient number of tubes to
last 2 weeks. Participants returned at 2 week intervals
for follow-up visits where vital signs, potential side
effects, use of the liquid cigarette product and carbon
monoxide levels were assessed; additional nicotine repla-
cement product (a 2 week supply) was distributed at
these visits for a total of 12 weeks of treatment. Subjects
also rated the liquid cigarette product on taste and over-
all satisfaction, each based on a 10 point scale (1-worst,
10-best) at each follow-up visit.
Outcomes
Consistent with established guidelines, cessation was
defined as an exhaled carbon monoxide (CO) level of
less than or equal to 8 parts per million (ppm) [11,12].
Participants who failed to complete appointments were
assumed to have returned to smoking.
Statistics
Sample size was determined using a one-sample chi-
squared statistic with inputs being a 5% type 1 error
rate, a null hypothesis that the proportion of persons
able to stop smoking using nicotine replacement therapy
is 0.22 [6,7], and 0.80 to be the probability of correctly
concluding efficacy if the true success proportion is
0.395 (= 0.22 + 0.175). Using the design calculator
NQuery 7.0, the required sample size is 50. Had the
design been one-sided and based on the one-sample
exact binomial distribution, the same inputs would have
required a sample of at least 44 subjects to conclude an
increased quit rate. Thus, the ITT and ATP sample
sizes are sufficiently large to accurately assess product
effectiveness. Demographic characteristics of those who
confirmed and those who failed to confirm participation
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duct satisfaction and adverse effects are summarized
using descriptive statistics. SPSS software (version 16.0,
SPSS, Inc., Chicago. IL) was used to facilitate analyses.
Results
Selected demographic and tobacco use characteristics of
study participants are summarized in table 1. Among
the 69 consented participants, 53.6% were female, 91.3%
were white, 29.0% were ages 35-44 years, 40.6% were
45-54 years and the remainder were age 55 year or
older. Most participants reported smoking either 20-29
daily cigarettes (44.9%) or 30+ daily cigarettes (43.5%)
and 85.5% reported having smoked for at least 20 years.
About 3/4 of study participants indicated that they
smoked their first cigarette within 30 minutes of awa-
kening consistent with significant nicotine addiction
[3,4]. The only variable which differed among those who
confirmed participation following the baseline visit and
those who did not was race, with non-whites less likely
to confirm participation. There were no serious adverse
events and no clinically meaningful variation in the vital
signs of the participants.
The rate of smoking cessation 12 weeks after the base-
line visit, measured as the bioverified point prevalence
of abstinence, was 71.1% (95% confidence interval [CI]
58.8%-83.5%) in the ATP group and 53.6% (41.8%-
65.4%) in the ITT group. In the ATP group, cessation
rates ranged from 84.9% at week 4 to 62.3% at week 8,
while in the ITT group cessation rates were 65.2% at
week 4 and 47.8% at week 8.
Participants consistently rated the Smoke-Break liquid
nicotine system highly on taste (median = 8 on a 10 point
scale) at all follow-up visits. Likewise, participants
consistently indicated robust overall satisfaction (median =
7) with the liquid nicotine cigarette product. Rating did
not differ among those who achieved cessation and those
who did not.
Overall, 17 of 52 participants (32.7%) who returned for
follow-up assessments reported some adverse event; no
one reported more than one potential adverse event. As
shown in table 2, only one of these was felt to be prob-
ably attributable to the liquid cigarette nicotine delivery
product. In all cases, reported symptoms fully resolved.
No serious adverse events occurred.
Discussion
Results from this single-arm Phase 2a study support the
efficacy of the liquid nicotine cigarette as an aid to
achieving smoking cessation. These estimates of cessa-
tion, bioverified through measurement of exhaled CO,
are interesting and warrant confirmation in subsequent
Phase 3 studies. It is possible that the manipulation of
the liquid cigarette product during use serves to provide
important tactile and oral stimulation to smokers during
their quit attempt.
Abstinence may be defined in a variety of ways[12].
Similar to approaches utilized for exploring new thera-
peutic interventions, this proof of concept trial relied
upon a measure of cessation at limited time points (e.g.,
point prevalence assessments at 2 week follow-up visits
over an interval of 12 weeks). It is important to note
that this measure of abstinence provides a useful and
relevant estimate of treatment effect size. In other
words, these results support the efficacy of this alterna-
tive nicotine replacement delivery formulation for smok-
ing cessation. However, until randomized comparative
trials are completed, we are unable to conclude whether
Figure 1 Identification of study participants in smoking cessation trial.
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observed with other forms of NRT including patches,
gum/resin and lozenges.
Continuous abstinence likely correlates strongly with
long term abstinence[12]. Data from this study suggest a
high rate of continuous abstinence, defined as
abstinence between 2 follow-up visits, among a majority
of our study participants. For example, 29 of the 37
(78%) participants who were smoke-free at the week 12
visit appeared to be continuously abstinent between vis-
its at week 4 and week 12. However, this interpretation
is based on repeated measures of point prevalence
Table 1 Selected demographic and tobacco use characteristics among study participants
confirmed participation (n = 52) failed to confirm participation (n = 17)
characteristic category n % n % p-value:
gender female 26 50.0% 11 64.7% p = 0.403
male 26 50.0% 6 35.3%
age group 25-44 yrs 13 25.0% 7 41.2% p = 0.435
45-54 yrs 22 42.3% 6 35.3%
55-68 yrs 17 32.7% 4 23.5%
race white 51 98.1% 12 70.6% p = 0.003
non-white 1 1.9% 5 29.4%
# daily cigarettes <20 cigs 6 11.5% 2 11.8% p = 0.622
20-29 cigs 20 42.3% 9 52.9%
30+ cigs 24 46.2% 6 35.3%
years smoked <20 yrs 7 13.5% 3 17.6% p = 0.909
20-29 yrs 25 48.1% 8 47.1%
30+ yrs 20 38.5% 6 35.3%
pack-years smoked <30 14 26.9% 7 41.2% p = 0.536
30-44 18 34.6% 5 29.4%
45-88 20 38.5% 5 29.4%
time to 1
st cigarette <30 min 37 71.2% 14 82.4% p = 0.528
30+ min 15 28.8% 3 17.6%
Intention to treat (ITT) group includes all 69 participants while the according to protocol (ATP) group includes the 52 participants who confirmed participation.
Table 2 Reports of adverse events among study participants (n = 52), with severity and attribution
adverse event # reporting severity attribution
diarrhea/loose stools 3 mild not attributable (n = 1); possible (n = 2)
dizzy/light headed 2 mild not attributable (n = 1); possible (n = 1)
stomach pains/gas 1 mild possible
heartburn 1 mild not attributable
gum swelling 1 mild not attributable
mouth sores 1 mild not attributable
sore throat 1 mild not attributable
nasal dryness/irritation 1 mild not attributable
upper respiratory congestion 1 mild not attributable
finger dislocation 1 mild not attributable
sleep problems 1 mild possible
skin infection 1 mild not attributable
eye infection 1 mild not attributable
constipation 1 mild not attributable
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overestimates the true rate of continuous abstinence
since the detection window for CO is approximately 24
hours[11]. On the other hand, it would be difficult for
participants to be smoke-free only on the days of fol-
low-up visits while continuing to smoke on other days.
Allowing a 2 week or 4 week grace period to assess con-
tinuous abstinence allows subjects to gain experience
with the therapeutic intervention and also to experience
slips and relapses that often occur in many smokers try-
ing to quit[12]. In addition, point prevalence measures
of abstinence also acknowledge the slips and relapses
which occur during a quit attempt. Potential biases and
limitations of this Phase 2a study include possible selec-
tion bias resulting from recruitment procedures and the
likelihood that long-term quit rates, at both 6 months
and 1 year, will be lower than those observed at 12
weeks.
Unlike over-the-counter (OTC) nicotine-replacement
products (patch, gum, lozenge), the Smoke-Break nico-
tine delivery system appears to address both the “oral
fixation,” and “hand-to-mouth” conditioned sensory and
motor aspects which characterize the smoking experi-
ence. The Smoke-Break cylinder-shaped nicotine deliv-
ery system was created to deliver a nicotine-containing,
liquid formulation. When placed between the lips, the
liquid in the cylinder is drawn into the mouth, much
like sipping through a straw. The liquid is held in the
mouth for a brief time and then swallowed partially
mimicking the action of smoking.
Similar to the vast experience with over-the-counter
nicotine replacement products [13], the nicotine delivery
system used in this study appears to be safe and well--
tolerated. Side effects of NRT mainly include local irrita-
tion (i.e., mouth sores, skin rash, nasal and throat
irritation) associated with the route of administration of
the medication (i.e., mouth, skin, nares); these side
effects were typically mild and transient[14].
While numerous studies have shown improved effi-
cacy when NRT is combined with professional counsel-
ing,[6] no formal counseling was made available to
s u b j e c t sd u r i n gt h i ss t u d y .P a r t i c i p a n t si nt h i ss t u d y
were able to direct questions to the study staff about the
product, and to discuss their experiences, every two
weeks, in lieu of professional counseling. Subsequent
clinical trials should consider a counseling component
in addition to the nicotine delivery system[6].
The provision of counseling support in a subsequent
trial may serve to further increase cessation rates with
the liquid nicotine dispenser, although a unique strength
of the present study is that the results appear to be gen-
eralizable to groups of smokers who opt not to make
use of counseling services. Although compelling, these
results require validation in a larger clinical trial with
attention to cessation rates across a longer follow-up
interval and exploration of effects among different
groups of smokers.
Conclusions
These results support the efficacy of the liquid cigarette
nicotine delivery system in smoking cessation as
assessed after 12 weeks of therapy. If this nicotine deliv-
ery product proves to be effective in larger trials, it
could represent an inexpensive, readily accessible and
well-tolerated agent to promote tobacco cessation.
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